Hypertension, Pulmonary Clinical Trial
— EXERTIONOfficial title:
Exercise Hemodynamic, Right Ventricular Coupling and Echocardiography in Pulmonary Hypertension
NCT number | NCT04663217 |
Other study ID # | AZ 11716 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | November 1, 2020 |
Est. completion date | November 4, 2023 |
Verified date | May 2024 |
Source | University of Giessen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
This study aims to investigate the exercise profile in pulmonary hypertension patients with either pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension or pulmonary hypertension due to left heart disease and in disease control.
Status | Completed |
Enrollment | 120 |
Est. completion date | November 4, 2023 |
Est. primary completion date | November 4, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Confirmed diagnosis of pulmonary arterial hypertension (World Health Organization group 1) - Pulmonary hypertension due to left heart disease (World Health Organization group 2) - Chronic thromboembolic pulmonary hypertension (World Health Organization group 4) - Invasive exclusion of pulmonary hypertension - Age = 18 years - Planned right heart catheterization based on clinical grounds - Stable specific PAH medications - Ability to undergo cycle ergometry - Signed informed consent Exclusion Criteria: - Other etiologic groups of pulmonary hypertension (World Health Organization group 3, 5) - Unstable or severe coronary artery disease - Uncontrolled arterial hypertension - Left ventricular ejection fraction < 30% - Severe congenital or acquired valvular or myocardial disease - Progressive left heart failure - History of severe ventricular arrhythmias - Severe, terminal renal impairment - Severe obstructive or restrictive lung disease - Severe lung emphysema or interstitial lung disease |
Country | Name | City | State |
---|---|---|---|
Germany | Kerckhoff-Klinik | Bad Nauheim | Hesse |
Germany | University of Giessen | Gießen | Hesse |
Lead Sponsor | Collaborator |
---|---|
University of Giessen |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | exercise pulmonary arterial pressure | mean pulmonary arterial pressure (mmHg) | 1 day | |
Primary | exercise cardiac output | cardiac output (l/min); | 1 day | |
Primary | exercise pulmonary wedge pressure | pulmonary arterial wedge pressure (mmHg) | 1 day | |
Primary | exercise arterial elastance | arterial elastance (mmHg/mL) | 1 day | |
Primary | exercise end-systolic elastance | end-systolic elastance (mmHg/mL) | 1 day | |
Primary | exercise mean right atrial pressure | mean right atrial pressure (mmHg) | 1 day | |
Primary | exercise right atrial function | right atrial strain (%) | 1 day | |
Primary | exercise right volume | right ventricular volume (ml) | 1 day | |
Primary | exercise right ventriculare function | right ventricular strain (%) | 1 day | |
Primary | exercise right atrial volume-pressure curves | atrial volume to pressure ratio (ml/mmHg) | 1 day | |
Secondary | exercise lung congestion | B-Lines | 1 day | |
Secondary | exercise left atrial function | left atrial strain (%) | 1 day | |
Secondary | exercise left atrial volume | left atrial volume (ml) | 1 day | |
Secondary | exercise hepatic backflow | diameter inferior vena cava (mm) | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04095286 -
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
|
Phase 1 | |
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT02191137 -
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
|
Phase 4 | |
Completed |
NCT01959828 -
Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery
|
Phase 3 | |
Withdrawn |
NCT01202045 -
Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
|
N/A | |
Completed |
NCT01121458 -
Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed
|
Phase 4 | |
Completed |
NCT00963027 -
Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
Completed |
NCT00963001 -
Effect of Food on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
Terminated |
NCT00825266 -
Insulin Resistance in Pulmonary Arterial Hypertension
|
Phase 4 | |
Terminated |
NCT00384865 -
A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
|
Phase 2 | |
Active, not recruiting |
NCT03926572 -
Acute Decompensation of Pulmonary Hypertension
|
N/A | |
Completed |
NCT02826252 -
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
|
N/A | |
Completed |
NCT02545465 -
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
|
N/A | |
Recruiting |
NCT04498299 -
Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
|
||
Recruiting |
NCT02558582 -
Effect of Exercise Training in Patients With Pulmonary Hypertension
|
N/A | |
Active, not recruiting |
NCT02562235 -
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
|
Phase 3 | |
Completed |
NCT02755298 -
Chronic Clinical Effect of Acetazolamide
|
Phase 2/Phase 3 | |
Terminated |
NCT03043976 -
Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension
|
N/A | |
Completed |
NCT02576002 -
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
|
N/A | |
Completed |
NCT01178073 -
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
|
Phase 3 |